Original Publications

  1. Kuzin M, Schoretsanitis G, Haen E, Stegmann B, Hiemke C, Gründer G, Paulzen M (2017) Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. Clin Pharmacokinet.2017 Sep 2. doi: 10.1007/s40262-017-0591-8. [Epub ahead of print]
  1. Paulzen M, Goecke TW, Stingl JC, Janssen G, Stickeler E, Gründer G, Schoretsanitis G (2017) Pregnancy exposure to citalopram – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. Prog Neuropsychopharmacol Biol Psychiatry 2017 Jun 26. pii: S0278-5846(17)30357-3. doi: 10.1016/j.pnpbp.2017.06.030. [Epub ahead of print]
  1. Paulzen M, Schoretsanitis G, Stegmann B, Hiemke C, Gründer G, Schruers KRJ, Walther S, Lammertz SE, Haen E (2017) Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 76: 101-106
  1. Paulzen M, Haen E, Hiemke C, Stegmann B, Lammertz SE, Gründer G, Schoretsanitis G (2017) Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. Br J Clin Pharmacol 2017 Feb 4. doi: 10.1111/bcp.13255. [Epub ahead of print]
  1. Paulzen M, Goecke TW, Stickeler E, Gründer G, Schoretsanitis G (2017) Sertraline in pregnancy – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. J Affect Disord 212: 1-6
  1. Schoretsanitis G, Haen E, Stegmann B, Hiemke C, Gründer G, Paulzen M (2017) Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism. Schizophr Res 185: 51-57
  1. Goerlich KS, Votinov M, Lammertz SE, Winkler L, Spreckelmeyer KN, Habel U, Gründer G, Gossen A (2017) Effects of alexithymia and empathy on the neural processing of social and monetary rewards. Brain Struct Funct 2016 Nov 19. [Epub ahead of print]
  1. Schoretsanitis G, Haen E, Gründer G, Stegmann B, Schruers KR, Hiemke C, Lammertz SE, Paulzen M (2016) Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. J Clin Psychopharmacol 36: 554-561
  1. Deuse L, Rademacher LM, Winkler L, Schultz RT, Gründer G, Lammertz SE (2016) Neural correlates of naturalistic social cognition: brain-behavior relationships in healthy adults. Soc Cogn Affect Neurosci 11: 1741-1751
  1. Paulzen M, Haen E, Stegmann B, Unterecker S, Hiemke C, Gründer G, Schoretsanitis G (2017) Clinical response in a risperidone-medicated naturalistic sample: patients’ characteristics and dose-dependent pharmacokinetic patterns. Eur Arch Psychiatry Clin Neurosci 267: 325-333
  1. Gründer G, Bauer M, Deuschle M, Hautzinger M, Friede M, Müller MJ (2017) [Rank of outcome parameters in the treatment of depression : Results of a Delphi panel survey]. Nervenarzt 2016 Aug 9. [Epub ahead of print]
  1. Paulzen M, Haen E, Stegmann B, Hiemke C, Gründer G, Lammertz SE, Schoretsanitis G (2016) Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. Psychoneuroendocrinology 73: 9-15
  1. Mobascher A, Diaz-Lacava A, Wagner M, Gallinat J, Wienker TF, Drichel D, Becker T, Steffens M, Dahmen N, Gründer G, Thürauf N, Kiefer F, Kornhuber J, Toliat MR, Thiele H, Nürnberg P, Steinlein O, Winterer G (2016) Association of Common Polymorphisms in the Nicotinic Acetylcholine Receptor Alpha4 Subunit Gene with an Electrophysiological Endophenotype in a Large Population-Based Sample. PLoS One 2016 Apr 7;11(4):e0152984
  1. Paulzen M, Haen E, Gründer G, Stegmann B, Schruers KJR, Lammertz SE, Schoretsanitis G (2016) Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients – thinking of clinically relevant CYP2D6 interactions. J Psychopharmacology 30: 803-809
  1. Pfeifer P, Tüscher O, Buchholz HG, Gründer G, Vernaleken I, Paulzen M, Zimmermann US, Maus S, Lieb K, Eggermann T, Fehr C, Schreckenberger M (2017) Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2/D3 dopamine system. Addiction Biology, in press
  1. Schoretsanitis G, Stegmann B, Hiemke H, Gründer G, Schruers KJR, Walther S, Lammertz SE, Haen E, Paulzen M (2016) Pharmacokinetic Patterns of Risperidone – associated Adverse Drug Reactions. Eur J Clin Pharmacol 72: 1091-1098
  1. Schoretsanitis G, Haen E, Hiemke H, Gründer G, Stegmann B, Schruers KJR, Veselinovic T, Lammertz SE, Paulzen M (2016) Risperidone induced Extrapyramidal Side Effects – Is the need for Anticholinergics the Consequence of high Plasma Concentrations? Int Clin Psychopharmacol 31: 259-264
  1. Gründer G, Heinze M, Cordes J, Mühlbauer B, Juckel G, Schulz C, Rüther E, Timm J (2016) Effects of first- versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind randomised study. Lancet Psychiatry 3: 717-729
  1. Schulz C, Timm J, Cordes J, Gründer G, Mühlbauer B, Rüther E, Heinze M (2016) Patient-oriented randomisation — a new trial design applied in the Neuroleptic Strategy Study (NeSSy). Clin Trials 13: 251-259
  1. Rademacher L, Prinz S, Winz O, Henkel K, Dietrich CA, Schmaljohann J, Mohammadkhani Shali S, Schabram I, Stoppe C, Cumming P, Hilgers RD, Kumakura Y, Coburn M, Mottaghy FM, Gründer G, Vernaleken I (2016) Effects of Smoking Cessation on Presynaptic Dopamine Function of Addicted Male Smokers. Biol Psychiatry 80: 198-206
  1. Paulzen M, Lammertz SE, Gründer G, Veselinovic T, Hiemke C, Tauber SC (2016) Measuring citalopram in blood and central nervous system: revealing a distribution pattern that differs from other antidepressants. Int Clin Psychopharmacol 31: 119-126
  1. Bey K, Lennertz L, Markett S, Petrovsky N, Gallinat J, Gründer G, Spreckelmeyer KN, Wienker TF, Mobascher A, Dahmen N, Thuerauf N, Kornhuber J, Kiefer F, Toliat MR, Nürnberg P, Winterer G, Wagner M (2016) Replication of the association between CHRNA4 rs1044396 and harm avoidance in a large population-based sample. Eur Neuropsychopharmacol 26: 150-155
  1. Paulzen M, Gründer G, Veselinovic T, Wolf B, Hiemke C, Lammertz SE (2015) Duloxetine enters the brain – But why is it not found in the cerebrospinal fluid. J Affect Disord 189: 159-163
  1. Paulzen M, Lammertz SE, Veselinovic T, Goecke TW, Hiemke C, Gründer G (2015) Lamotrigine in pregnancy – therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. Int Clin Psychopharmacol 30: 249-254
  1. Veselinović T, Vernaleken I, Janouschek H, Kellermann T, Paulzen M, Cumming P, Gründer G (2015) Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. Psychopharmacology (Berl) 232: 1607-1617
  1. Paulzen M, Groppe S, Tauber SC, Veselinovic T, Hiemke C, Gründer G (2015) Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid. J Clin Psychiatry 76: 25-31
  1. Paulzen M, Gründer G, Tauber SC, Veselinovic T, Hiemke C, Groppe SE (2015) Distribution pattern of mirtazapine and normirtazapine in blood and CSF. Psychopharmacology (Berl) 232: 807-813
  1. Schabram I, Henkel K, Mohammadkhani Shali S, Dietrich C, Schmaljohann J, Winz O, Prinz S, Rademacher L, Neumaier B, Felzen M, Kumakura Y, Cumming P, Mottaghy FM, Gründer G, Vernaleken I (2014) Acute and sustained effects of methylphenidate on cognition and presynaptic dopamine metabolism: an [18F]FDOPA PET study. J Neurosci 34: 14769-14776
  1. Prinz S, Gründer G, Hilgers RD, Holtemöller O, Vernaleken I (2014) Impact of personal economic environment and personality factors on individual financial decision making. Front Psychol 5: 158
  1. Piel M, Schmitt U, Bausbacher N, Buchholz HG, Gründer G, Hiemke C, Rösch F (2014) Evaluation of P-glycoprotein (abcb1a/b) modulation of [18F]fallypride in MicroPET imaging studies. Neuropharmacology 84: 152-158
  1. Cohrs S, Rodenbeck A, Riemann D, Szagun B, Jaehne A, Brinkmeyer J, Gründer G, Wienker T, Diaz-Lacava A, Mobascher A, Dahmen N, Thuerauf N, Kornhuber J, Kiefer F, Gallinat J, Wagner M, Kunz D, Grittner U, Winterer G (2014) Impaired sleep quality and sleep duration in smokers-results from the German Multicenter Study on Nicotine Dependence. Addict Biol 19: 486-496
  1. Gossen A, Winkler L, Groppe SE, Kohls G, Herrington J, Schultz RT, Gründer G, Spreckelmeyer KN (2014) Neural evidence for an association between social proficiency and sensitivity to social reward. Soc Cogn Affect Neurosci 9: 661-670
  1. Rademacher L, Salama A, Gründer G, Spreckelmeyer KN (2014) Differential patterns of nucleus accumbens activation during anticipation of monetary and social reward in young and older adults. Soc Cogn Affect Neurosci 9: 825-831
  1. Kumakura Y, Gjedde A, Caprioli D, Kienast T, Beck A, Plotkin M, Schlagenhauf F, Vernaleken I, Gründer G, Bartenstein P, Heinz A, Cumming P (2013) Increased turnover of dopamine in caudate nucleus of detoxified alcoholic patients. PLoS One 8(9): e73903
  1. Schlüter T, Winz O, Henkel K, Prinz S, Rademacher L, Schmaljohann J, Dautzenberg K, Cumming P, Kumakura Y, Rex S, Mottaghy F, Gründer G, Vernaleken I (2013) The Impact of Dopamine on Aggression: An [18F]-FDOPA PET Study in Healthy Males. J Neurosci 33: 16889-16896
  1. Schabram I, Eggermann T, Siegel SJ, Gründer G, Zerres K, Vernaleken I (2013) Neuropsychological correlates of transcription factor AP-2Beta, and its interaction with COMT and MAOA in healthy females. Neuropsychobiology 68: 79-90
  1. Drueke B, Schlaegel SM, Seifert A, Moeller O, Gründer G, Gauggel S, Boecker M (2013) The role of 5-HT in response inhibition and re-engagement. Eur Neuropsychopharmacol 23: 830-841
  1. Mutschler J, Abbruzzese E, Wiedemann K, von der Goltz C, Dinter C, Mobascher A, Thiele H, Diaz-Lacava A, Dahmen N, Gallinat J, Majic T, Petrovsky N, Thuerauf N, Kornhuber J, Gründer G, Rademacher L, Brinkmeyer J, Wienker T, Wagner M, Winterer G, Kiefer F (2013) Functional Polymorphism in the Neuropeptide Y Gene Promoter (rs16147) Is Associated with Serum Leptin Levels and Waist-Hip Ratio in Women. Ann Nutr Metab 62: 271-276
  1. Kienast T, Schlagenhauf F, Rapp MA, Wrase J, Daig I, Buchholz HG, Smolka MN, Gründer G, Kumakura Y, Cumming P, Charlet K, Bartenstein P, Hariri AR, Heinz A (2013) Dopamine-Modulated Aversive Emotion Processing Fails in Alcohol-Dependent Patients. Pharmacopsychiatry 46: 130-136
  1. Groppe SE, Gossen A, Rademacher L, Hahn A, Westphal L, Gründer G, Spreckelmeyer KN (2013) Oxytocin influences processing of socially relevant cues in the ventral tegmental area of the human brain. Biol Psychiatry 74: 172-179
  1. Mutschler J, Abbruzzese E, von der Goltz C, Dinter C, Mobascher A, Thiele H, Diaz-Lacava A, Dahmen N, Gallinat J, Majic T, Petrovsky N, Thuerauf N, Kornhuber J, Gründer G, Rademacher L, Brinkmeyer J, Wienker T, Wagner M, Winterer G, Kiefer F (2013) Lack of Association of a Functional Catechol-O-Methyltransferase Gene Polymorphism With Risk of Tobacco Smoking: Results From a Multicenter Case-Control Study. Nicotine Tob Res 15: 1322-1327
  1. Cumming P, Xiong G, la Fougère C, Rominger A, Bartenstein P, Buchholz H-G, Piel M, Rösch F, Gründer G, Vernaleken I (2012) Surrogate markers for cerebral blood flow correlate with [18F]-fallypride binding potential at dopamine D2/3 receptors in human striatum. Synapse 67: 199-203
  1. Spreckelmeyer KN, Rademacher L, Paulus FM, Gründer G (2012) Neural activation during anticipation of opposite-sex and same-sex faces in heterosexual men and women. NeuroImage 66C: 223-231
  1. Veselinović T, Schorn H, Vernaleken IB, Hiemke C, Zernig G, Gur R, Gründer G (2013) Effects of antipsychotic treatment on cognition in healthy subjects. J Psychopharmacol 27: 374-385
  1. Gossen A, Hahn A, Prinz S, Westphal L, Schultz RT, Gründer G, Spreckelmeyer KN (2012) Oxytocin plasma concentrations after single intranasal oxytocin administration – a study in healthy men. Neuropeptides 46: 211-215
  1. Vernaleken I, Klomp M, Möller O, Raptis M, Nagels A, Rösch F, Schäfer WM, Cumming P, Gründer G (2012) Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. Int J Neuropsychopharmacol 20: 1-10
  1. Wagner M, Schulze-Rauschenbach S, Petrovsky N, Brinkmeyer J, von der Goltz C, Gründer G, Spreckelmeyer KN, Wienker T, Diaz-Lacava A, Mobascher A, Dahmen N, Clepce M, Thuerauf N, Kiefer F, de Millas JW, Gallinat J, Winterer G (2013) Neurocognitive impairments in non-deprived smokers-results from a population-based multi-center study on smoking-related behavior. Addict Biol 18: 752-761
  1. Mutschler J, Abbruzzese E, von der Goltz C, Dinter C, Mobascher A, Thiele H, Diaz-Lacava A, Dahmen N, Gallinat J, Majic T, Petrovsky N, Kornhuber J, Thuerauf N, Gründer G, Brinkmeyer J, Wienker T, Wagner M, Winterer G, Kiefer F (2012) Genetic Variation in the Neuropeptide Y Gene Promoter Is Associated with Increased Risk of Tobacco Smoking. Eur Addict Res 18: 246-252
  1. Quednow B, Brinkmeyer J, Mobascher A, Nothnagel M, Musso F, Gründer G, Savary N, Frommann I, Lennertz L, Spreckelmeyer KN, Wienker TF, Dahmen N, Thuerauf N, Clepce M, Kiefer F, Majic T, Mössner R, Maier W, Gallinat J, Diaz-Lacava A, Reza Toliat M, Thiele H, Nürnberg P, Wagner M, Winterer G (2012) Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating. Proc Natl Acad Sci USA 109: 6271-6276
  1. Kuhn J, Janouschek H, Raptis M, Rex S, Lenartz D, Neuner I, Mottaghy FM, Schneider F, Schaefer WM, Sturm V, Gründer G, Vernaleken I (2012) In vivo evidence of deep brain stimulation-induced dopaminergic modulation in Tourette’s syndrome. Biol Psychiatry 71: e11-13
  1. Spreckelmeyer KN, Paulzen M, Raptis M, Baltus T, Schaffrath S, Van Waesberghe J, Zalewski MM, Rösch F, Vernaleken I, Schäfer WM, Gründer G (2011) Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)F]fallypride positron emission tomography study. Biol Psychiatry 70: 770-776
  1. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, Jarkova N; and the HBBI Study Group (including Gründer G) (2011) A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 31: 349-355
  1. Veselinović T, Schorn H, Vernaleken I, Schiffl K, Hiemke C, Zernig G, Gur R, Gründer G (2011) Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo controlled study in healthy volunteers. Psychopharmacology 218: 733-748
  1. Lindenberg A, Brinkmeyer J, Dahmen N, Gallinat J, de Millas W, Mobascher A, Wagner M, Schulze-Rauschenbach S, Gründer G, Spreckelmeyer KN, Clepce M, Thürauf N, von der Goltz C, Kiefer F, Steffens M, Holler D, Díaz-Lacava A, Wienker T, Winterer G (2011) The German multi-centre study on smoking-related behavior-description of a population-based case-control study. Addict Biol 16: 638-653
  1. Brinkmeyer J, Mobascher A, Musso F, Schmitz M, Wagner M, Frommann I, Gründer G, Spreckelmeyer KN, Wienker T, Díaz-Lacava A, Holler D, Dahmen N, Thuerauf N, Clepce M, Kiefer F, de Millas W, Gallinat J, Winterer G (2011) P50 sensory gating and smoking in the general population. Addict Biol 16: 485-498
  1. Koopmann A, Dinter C, Grosshans M, von der Goltz C, Hentschel R, Dahmen N, Gallinat J, Wagner M, Gründer G, Thürauf N, Wienker T, Brinkmeyer J, Mobascher A, Spreckelmeyer KN, Clepce M, de Millas W, Wiedemann K, Winterer G, Kiefer F (2011) Psychological and hormonal features of smokers at risk to gain weight after smoking cessation – Results of a multicenter study. Horm Behav 60: 58-64
  1. Vernaleken I, Peters L, Raptis M, Lin R, Buchholz HG, Zhou Y, Winz O, Rösch F, Bartenstein P, Wong DF, Schaefer WM, Gründer G (2011) The applicability of SRTM in [18F]fallypride PET investigations: impact of scan durations. J Cereb Blood Flow Metab 31: 1958-1966
  1. Bernow B, Yakushev I, Landvogt C, Buchholz H-G, Smolka M, Bartenstein P, Lieb K, Gründer G, Vernaleken I, Schreckenberger M, Fehr C (2011) Dopamine D2/D3 receptor availability and venturesomeness. Psychiatr Res – Neuroimaging 193: 80-84
  1. Veselinović T, Schorn H, Vernaleken I, Schiffl K, Klomp M, Gründer G (2011) Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol 31: 214-220
  1. Drueke B, Boecker M, Schlaegel S, Moeller O, Hiemke C, Gründer G, Gauggel S (2010) Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers. Hum Psychopharmacol Clin Exp 25: 472-480
  1. Mobascher A, Brinkmeyer J, Warbrick T, Wels C, Wagner M, Gründer G, Spreckelmeyer KN, Wienker T, Diaz Lacava A, Dahmen N, Böttcher M, Thuerauf N, Clepce M, Kiefer F, De Millas W, Gallinat J, Winterer G (2010) The P300 event-related potential and smoking – A population-based case-control study. Int J Psychophysiol 77: 166-175
  1. Nazirizadeh Y, Vogel F, Bader W, Haen E, Pfuhlmann B, Gründer G, Paulzen M, Schwarz M, Zernig G, Hiemke C (2010) Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol 66: 797-803
  1. Kobiella A, Vollstäst-Klein S, Bühler M, Graf C, Buchholz H-G, Bernow N, Yakushev I, Landvogt C, Schreckenberger M, Gründer G, Bartenstein P, Fehr C, Smolka MN (2010) Human dopamine receptor D2/D3 availability predicts amygdale reactivity to aversive stimuli. Hum Brain Mapp 31: 716-726
  1. Vernaleken I, Janouschek H, Raptis M, Hellmann S, Veselinovic T, Bröcheler A, Boy C, Cumming P, Hiemke C, Rösch F, Schäfer WM, Gründer G (2010) Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. Int J Neuropsychopharmacol 15: 1-10
  1. Kumakura Y, Vernaleken I, Buchholz H-G, Borghammer P, Danielsen EH, Gründer G, Heinz A, Bartenstein P, Cumming P (2010) Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study. Neurobiol Aging 31: 447-63
  1. Kumakura Y, Danielsen EH, Gjedde A, Vernaleken I, Buchholz HG, Heinz A, Gründer G, Bartenstein P, Cumming P (2010) Elevated [(18)F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson’s disease. NeuroImage 49: 2933-2939
  1. Rademacher L, Krach S, Kohls G, Irmak A, Gründer G, Spreckelmeyer KN (2010) Dissociation of neural networks for anticipation and consumption of monetary and social rewards. NeuroImage 49: 3276-3285
  1. Drueke B, Baetz J, Boecker M, Moeller O, Hiemke C, Gründer G, Gauggel S (2009) Differential effects of 5-HT on attention: a placebo-controlled, double-blind cross-over study. Psychopharmacology 207: 213-223
  1. Spreckelmeyer KN, Krach S, Kohls G, Rademacher L, Irmak A, Konrad K, Kircher T, Gründer G (2009) Anticipation of monetary and social reward differently activates mesolimbic brain structures in men and women. Soc Cogn Affect Neurosci 4: 158-165
  1. Vogel F, Gansmüller R, Leiblein T, Dietmeier O, Wassmuth H, Gründer G, Hiemke C (2009) The use of ziprasidone in clinical practice. Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. Eur Psychiatry 24: 143-148
  1. Kienast T, Hariri AR, Schlagenhauf F, Wrase J, Sterzer P, Buchholz H-G, Smolka M, Gründer G, Cumming P, Kumakura Y, Bartenstein P, Dolan RJ, Heinz A (2008) Dopamine storage capacity in the amygdala gates processing of aversive stimuli in amygdala and anterior cingulate cortex: a combined PET – fMRI study. Nat Neurosci 11: 1381-1382
  1. Vernaleken I, Fellows C, Janouschek H, Bröcheler A, Veselinivic T, Landvogt C, Boy C, Buchholz H-G, Bartenstein P, Cumming P, Hiemke C, Rösch F, Schaefer WM, Wong DF, Gründer G (2008) Striatal and extrastriatal D2/3 receptor binding properties of ziprasidone: a PET study with [18F]fallypride and [11C]raclopride. J Clin Psychopharmacol 28: 608-617
  1. Schreckenberger M, Heinz A, Gründer G, Buchholz H-G, Scheurich A, Schirrmacher R, Schirrmacher E, Klega A, Müller C, Piel M, Rösch F, Henriksen G, Wester H-J, Treede R-D, Bartenstein P (2008) Opioid receptor PET reveals the neurobiological correlates of addiction- and reinforcement-related personality traits. J Nucl Med 49: 1257-1261
  1. Reimold M, Batra A, Knobel A, Smolka MN, Zimmer A, Mann K, Solbach C, Reischl G, Schwärzler F, Gründer G, Machulla HJ, Bares R, Heinz A (2008) Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [(11)C]DASB PET study. Mol Psychiatry 13: 606-13,557
  1. Meisenzahl EM, Schmitt G, Gründer G, Dresel S, Frodl T, la Fougère C, Scheuerecker J, Schwarz M, Boerner R, Stauss J, Hahn K, Möller, H-J (2008) Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 41(5): 169-75
  1. Vernaleken I, Kumakura Y, Buchholz H-G, Siessmeier T, Bartenstein P, Cumming P, Gründer G (2008) Baseline [18F]FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron-emission-tomography study in healthy subjects. NeuroImage 40: 1222-1231
  1. Gründer G, Fellows C, Janouschek H, Veselinovic T, Boy C, Bröcheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rösch F, Schaefer WM, Vernaleken I (2008): The brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: a [18F]fallypride PET study. Am J Psychiatry 165: 988-995
  1. Kienast T, Siessmeier T, Wrase J, Braus DF, Smolka MN, Buchholz HG, Rapp M, Schreckenberger M, Rösch F, Cumming P, Gruender G, Mann K, Bartenstein P, Heinz A (2008) Ratio of dopamine synthesis capacity to D2 receptor availability in ventral striatum correlates with central processing of affective stimuli. Eur J Nucl Med Mol Imaging 35: 1147-58
  1. Fehr C, Yakushev I, Hohmann N, Buchholz H-G, Landvogt C, Deckers H, Eberhardt A, Kläger M, Smolka MN, Scheurich A, Dielentheis T, Schmidt LG, Rösch F, Bartenstein P, Gründer G, Schreckenberger M (2008) Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry 165: 507-514
  1. Stark D, Piel M, Hübner H, Gmeiner P, Gründer G, Rösch F (2007) In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(d)-like dopamine receptors. Bioorg Med Chem 15: 6819-6829
  1. Kumakura Y, Cumming P, Vernaleken I, Buchholz H-G, Siessmeier T, Heinz A, Kienast T, Bartenstein P, Gründer G (2007) Elevated dopamine turnover in striatum of patients with schizophrenia; an [18F]FDOPA/PET study. J Neurosci 27: 8080-8087
  1. Schlösser R, Gesierich T, Wagner G, Bolz M, Gründer G, Dielentheis TF, Scherb C, Stoeter P (2007) Altered benzodiazepine receptor sensitivity in alcoholism: a study with fMRI and acute lorazepam challenge. Psychiatry Res (Neuroimaging) 154: 241-251
  1. Vernaleken I, Buchholz H-G, Kumakura Y, Siessmeier T, Stoeter P, Bartenstein P, Cumming P, Gründer G (2007) „Prefrontal“ cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET investigation. Hum Brain Mapp 28: 931-939
  1. Vernaleken I, Weibrich C, Siessmeier T, Buchholz HG, Rosch F, Heinz A, Cumming P, Stoeter P, Bartenstein P, Gründer G (2007) Asymmetry in dopamine D(2/3) receptors of caudate nucleus is lost with age. NeuroImage 34: 870-878
  1. Fehr C, Hohmann N, Gründer G, Dielentheis TF, Buchholz HG, Chechko N, Yakushev I, Landvogt C, Bartenstein P, Urban R, Schreckenberger M (2007) Tiagabine does not attenuate alcohol-induced activation of the human reward system. Psychopharmacology 191: 975-983
  1. Vernaleken I, Kumakura Y, Cumming P, Buchholz H-G, Siessmeier T, Stoeter P, Müller MJ, Bartenstein P, Gründer G (2006) Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. NeuroImage 30: 1332-1339
  1. Gründer G, Landvogt C, Vernaleken I, Buchholz H-G, Ondracek J, Siessmeier T, Härtter S, Schreckenberger M, Stoeter P, Hiemke C, Rösch F, Wong DF, Bartenstein P (2006) The striatal and extrastriatal D2/D3 receptor binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31: 1027-1035
  1. Heinz A, Siessmeier T, Wrase J, Buchholz H-G, Gründer G, Kumakura Y, Cumming P, Schreckenberger M, Smolka MN, Rösch F, Mann K, Bartenstein P (2005) Alcohol craving correlates with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined FDOPA and DMFP PET study in detoxified alcoholics. Am J Psychiatry 162: 1515-1520
  1. Siessmeier T, Zhou Y, Buchholz H-G, Landvogt C, Vernaleken I, Piel M, Schirrmacher R, Rösch F, Schreckenberger M, Wong DF, Cumming P, Gründer G, Bartenstein P (2005) Parametric Mapping of the Binding in Human Brain of D2-Receptor Ligands of Different Affinities. J Nucl Med 46: 964-972
  1. Kumakura Y, Vernaleken I, Gründer G, Bartenstein P, Gjedde A, Cumming P (2005) PET studies of net blood-brain clearance of FDOPA to human brain: age-dependent bias due to presence of the brain-penetrating plasma metabolite. J Cereb Blood Flow Metab 25: 807-819
  1. Heinz A, Siessmeier T, Wrase J, Hermann D, Klein S, Grüsser SM; Flor H, Braus DF, Buchholz H-G, Gründer G, Schreckenberger M, Smolka MN, Rösch F, Mann K, Bartenstein P (2004) Correlation between dopamine D2 receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry 161: 1783-1789
  1. Schreckenberger M, Hägele S, Siessmeier T, Buchholz H-G, Armbrust-Henrich H, Rösch F, Gründer G, Bartenstein P, Vogt T (2004) The dopamine D2-receptor ligand 18F-desmethoxyfallypride is an appropriate PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 31: 1128-1135
  1. Schreckenberger M, Amberg R, Scheurich A, Lochmann M, Tichy W, Klega A, Siessmeier T, Gründer G, Buchholz H-G, Landvogt C, Stauss J, Mann K, Bartenstein P, Urban R (2004) Acute Alcohol Effects on Neuronal and Attentional Processing: Striatal Reward System and Inhibitory Sensory Interactions under Acute Ethanol Challenge. Neuropsychopharmacology 29: 1527-2537
  1. Connemann BJ, Mann K, Lange-Asschenfeldt C, Ruchsow M, Schreckenberger M, Bartenstein P, Gründer G (2005) Anterior limbic alpha-like activity: an EEG study using low resolution electromagnetic tomography. Clin Neurophysiol 116: 886-894
  1. Vernaleken I, Siessmeier T, Buchholz H-G, Härtter S, Hiemke C, Stoeter P, Rösch F, Bartenstein P, Gründer G (2004) High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacology 7: 421-430
  1. Schreckenberger M, Lange-Asschenfeldt C, Lochmann M, Mann K, Siessmeier T, Buchholz H-G, Bartenstein P, Gründer G (2004) The thalamus as the generator and modulator of EEG alpha rhythm: a combined PET/EEG study with lorazepam challenge in humans. NeuroImage 22: 637-644
  1. Gründer G, Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60: 974-977
  1. Gründer G, Vernaleken I, Müller MJ, Davids E, Heydari N, Buchholz H-G, Bartenstein P, Munk O, Stoeter P, Wong DF, Gjedde A, Cumming P (2003) Subchronic haloperidol downregulates dopamine synthesis capacity in brain of schizophrenic patients in vivo. Neuropsychopharmacology 28: 787-794
  1. Gründer G, Siessmeier T, Piel M, Vernaleken I, Buchholz H-G, Zhou Y, Hiemke C, Wong DF, Rösch F, Bartenstein P (2003) Quantification of D2-like dopamine receptors in the human brain with [18F]desmethoxyfallypride. J Nucl Med 44: 109-116
  1. Gründer G, Benkert O (2002) Prolactin secretion is not a core dimension of atypicality. Psychopharmacology 162: 93
  1. Schlösser R, Gründer G, Anghelescu I, Hillert A, Ewald-Gründer S, Hiemke C, Benkert O (2002) Long term effects of the substituted benzamide antipsychotic amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 46: 33-40
  1. Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC-14,597): A study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27: 248-259
  1. Gründer G, Siessmeier T, Lange-Asschenfeldt C, Vernaleken I, Buchholz H-G, Stoeter P, Drzezga A, Lüddens H, Rösch F, Bartenstein P (2001) PET imaging of benzodiazepine receptors in the human brain with [18F]fluoroethylflumazenil. Eur J Nucl Med 28: 1463-1470
  1. Müller MJ, Gründer G, Wetzel H, Müller-Siecheneder F, Marx-Dannigkeit P, Benkert O (1999) Antipsychotic effects and tolerability of the putative sigma ligand panamesine (EMD 57445) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Res 89: 275-280
  1. Gründer G, Müller MJ, Andreas J, Wetzel H, Heydari N, Schlösser R, Schlegel S, Nickel O, Eissner D, Benkert O (1999) Occupancy of striatal D2-like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic. Psychopharmacology 146: 81-86
  1. Gründer G, Wetzel H, Schlößer R, Hillert A, Anghelescu I, Lange K, Hiemke C, Benkert O (1999) Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 45: 89-97
  1. Wetzel H, Gründer G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Schröder J, Rein W, Benkert O, and the Amisulpride Study Group (1998) Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology – a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-antagonist. Psychopharmacology 137: 223-232
  1. Gründer G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, Szymanski S, Wilson PD, Howard DR, Wong DF (1997) Time course of central 5-HT2 receptor occupancy after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomogra Neuropsychopharmacology 17: 175-185
  1. Benkert O, Gründer G, Wetzel H, Hackett D (1996) A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with depression and melancholia. J Psychiatr Res 30: 441-451
  1. Gründer G, Wetzel H, Schlößer R, Benkert O (1996) Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24 hour monitoring. Pharmacopsychiatry 29: 72-78
  1. Gründer G, Wetzel H, Hillert A, Jochum E, Hiemke C, Benkert O (1995) The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients. Psychopharmacology 117: 472-478
  1. Wetzel H, Hillert A, Gründer G, Benkert O (1994) Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenia. Am J Psychiatry 151: 1499-1502
  1. Gründer G, Wetzel H, Hammes E, Benkert O (1993) Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psychopharmacology 111: 123-126